The Carlyle Group and its newly acquired life sciences arm Abingworth are seeking to make up to four-times their money at Australian eye therapies developer Opthea.
As Street Talk revealed on Thursday morning, Carlyle/ABW will tip up to $US170 million ($242 million) into Opthea in a bid to get the company’s lead therapeutic candidate OPT-302 to market.
Loading...
Anthony Macdonald is a Chanticleer columnist. He is a former Street Talk co-editor and has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies. Connect with Anthony on Twitter. Email Anthony at a.macdonald@afr.com
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
